The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data. [electronic resource]
Producer: 20071026Description: 39-46 p. digitalISSN:- 1524-4733
- Aged
- Angiogenesis Inducing Agents -- economics
- Becaplermin
- Cost-Benefit Analysis -- methods
- Diabetic Foot -- classification
- Humans
- Markov Chains
- Middle Aged
- Platelet-Derived Growth Factor -- economics
- Proto-Oncogene Proteins c-sis
- Severity of Illness Index
- Sweden
- Treatment Outcome
- United States
- Wound Healing -- drug effects
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.